Menu
BLB research publications
- Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease
This original manuscript depicts the beneficial effects, and underlying mechanisms, of the pan-ppar agonist lanifibranor on portal hypertension and liver fibrosis in advanced chronic liver disease.
- A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease
This original study demonstrates that a nutraceutical rich in DHA significantly improves portal hypertension in chronic liver disease mainly by suppressing inflammation and oxidative stress-driven hepatic stellate cell activation, encouraging its evaluation as a new treatment for portal hypertension and cirrhosis.
- New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease
This study defines BLB’s BarNa model: a pre-clinical model of moderate and advanced NASH that mimics the human disease, including pathophysiologic characteristics and transcriptomic signature. Read the entire work.
- Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte-Mediated Paracrine Mechanism
This study demonstrates that emricasan improves liver sinusoidal microvascular dysfunction in cirrhosis, which leads to marked amelioration in fibrosis, portal hypertension and liver function, in pre-clinical models of advanced cirrhosis.
- Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications
This original manuscript describes a new bioengineered device that mimics the human sinusoid in vitro, representing a novel method to study liver diseases and toxicology. The unique and BLB’s proprietary ExoLiver platform.
- Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.
This study demonstrates for the first time that liraglutide improves the liver sinusoidal milieu in pre-clinical models of cirrhosis, provides mechanistic insight, and altogether encourages the clinical evaluation of GLP-1 receptor agonists for the treatment of chronic liver disease.